Genprex to Showcase Innovative Gene Therapy Developments at 28th Annual H.C. Wainwright Global Investment Conference

AUSTIN, Texas – Genprex, Inc., noted for its groundbreaking work in gene therapies, is set to present crucial insights about its clinical and preclinical programs at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, scheduled from September 14 to 16 in New York City. This event will provide a platform for Genprex's executive leadership to share their vision and advancements, which could revolutionize treatment in oncology and diabetes.

Leadership Presentation Highlights

Ryan Confer, the President and CEO of Genprex, will lead the presentation, showcasing the company's flagship program, Reqorsa® Gene Therapy. This innovative therapy is in clinical development, specifically aimed at empowering patients suffering from non-small cell lung cancer and small cell lung cancer. Genprex aims to restore the tumor-suppressor function through its unique approach, which utilizes the systemic, non-viral ONCOPREX® Delivery System.

In addition to the oncology program, Confer will also discuss exciting developments related to Genprex's diabetes program, which is currently navigating through preclinical stages. Designed to address insulin-producing functions in diabetic patients, this program represents a significant step toward innovative treatment solutions for both Type 1 and Type 2 diabetes.

Marc Berger, MD, the Chief Medical Officer, and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing, will also participate in the conference. Together, they will engage in one-on-one meetings with interested investors, offering deeper insights into Genprex’s strategic direction and potential partnership opportunities.

Conference Details

- Date: Monday, September 14, 2026
- Time: 3:30 - 4:00 PM ET
- Location: Lotte New York Palace Hotel, Holmes I (4th Floor), New York, NY

Participants can request one-on-one meetings with Genprex management through H.C. Wainwright, enhancing opportunities for investors to understand the company's advancements and vision on a more personal level.

About Genprex, Inc.

Genprex stands at the forefront of biotechnological innovation, focusing on gene therapies that may change lives. The company’s lead candidate, Reqorsa®, is currently undergoing trials to evaluate its efficacy in improving outcomes for lung cancer patients. The therapy delivers the TUSC2 tumor suppressor gene directly to the tumor site using advanced lipid-based nanoparticles.

Furthermore, Genprex's preclinical diabetes program indicates tremendous potential in managing insulin production, aiming to provide transformative therapies for diabetes management in collaboration with leading academic and research institutions.

As part of its commitment to transparency, Genprex encourages interested parties to follow its developments and sign up for press releases via the company website or social media channels, including Twitter, Facebook, and LinkedIn.

While the effects and future success of these initiatives remain contingent on numerous factors and regulatory pathways, Genprex’s commitment to innovation may soon pave the way for effective therapies in oncology and diabetes management. Shareholders and potential investors are urged to consider the substantial opportunities that lie ahead for Genprex as it continues to navigate the complex biotechnology landscape.

Looking Forward

Genprex's forward-looking approach is bolstered by its scientific expertise, underscoring its potential to innovate in the biotechnology sector significantly. Amidst an evolving landscape in healthcare and biotechnology, maintaining a vested interest in companies like Genprex can prove essential for stakeholders aiming to capitalize on emerging developments in gene therapy and precision medicine.

In conclusion, Genprex's upcoming presentation at the H.C. Wainwright Global Investment Conference represents a pivotal moment for the company to showcase its advancements and discuss future directions. Keep an eye on this innovative company as it seeks to make significant contributions to cancer treatment and diabetes management through its cutting-edge research.